Drug Profile
PF 4523655
Alternative Names: PF-04523655; PF-4523655; PF-655; PFE-4523655; REDD-14-NP; RTP 801i-14; RTP-801iLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Quark Pharmaceuticals
- Class Eye disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 17 Jun 2015 Phase-II development is ongoing for diabetic macular oedema and wet age-related macular degeneration USA, European Union, Asia, Latin America and the Middle East
- 02 May 2012 Quark and Pfizer amend their licensing agreement for PF 4523655 to allow Quark to conduct a phase IIa trial of the product in patients with open-angle glaucoma
- 11 Aug 2011 PF 4523655 is no longer licensed to Pfizer